Pharvaris (PHVS) Free Cash Flow Growth (3y) (2023 - 2026)
Pharvaris (PHVS) Free Cash Flow Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,561.01 Bn | 66,560.72 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,911.11 Bn | 1,911.05 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.81 Bn | 463.02 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 122.92 Bn | 115.68 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 70.28 Bn | 61.53 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 31.42% |
| 10 | Pharvaris | 2.23 Bn | 1.94 Bn | - | -28.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.25% |
| Dec 31, 2025 | -28.54% |
| Sep 30, 2025 | -32.93% |
| Jun 30, 2025 | -32.55% |
| Mar 31, 2025 | -26.22% |
| Dec 31, 2024 | -37.75% |
| Sep 30, 2024 | -45.27% |
| Jun 30, 2024 | -27.82% |
| Mar 31, 2024 | -28.85% |
| Dec 31, 2023 | -34.08% |
| Sep 30, 2023 | 18,502.69% |
| Jun 30, 2023 | -23,050.65% |
| Mar 31, 2023 | -119.65% |